A new treatment option for patients with moderate-to-severe Atopic Dermatitis: Targeting the IL-31/IL-31R signaling pathway

Date: Friday 20 September 2019
Time: 08.30-09.30

Room: tba

Chair: Alain Taïeb (Bordeaux, France)


08.30-08.32 Welcome & Introduction
Alain Taïeb (Bordeaux, France)

08.32-08.50 Are patient needs being met?
Marjolein de Bruin-Weller (Utrecht, The Netherlands)

08.50-09.08 IL-31/IL-31RA: inflammation, nerves, and the skin barrier – implications for pathophysiology of atopic dermatitis
Bernhard Homey (Düsseldorf, Germany)

09.08-09.26 Clinical perspectives in moderate-to-severe AD: Targeting IL-31/IL-31R
Jean David Bouaziz (Paris, France)

09.26-09.30 Conclusions – Q&A
Alain Taïeb (Bordeaux, France)